Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors: Implications for immune privilege and immune escape

Cancer

Volumn 94, Issue 10, 2002, Pages 2552-2560

  Bernstorff, Wolfram V ^a,b   Glickman, Jonathan N ^a   Odze, Robert D ^a   Farraye, Francis A ^a,c   Joo, Hong G ^a,d   Goedegebuure, Peter S ^a,d   Eberlein, Timothy J ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fas; Fas ligand; Immune escape; Immune privilege; Immunohistochemistry; Pancreas; Survival

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; IMMUNOSURVEILLANCE; LIGAND BINDING; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, DUCTAL, BREAST; CHRONIC DISEASE; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREAS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATITIS; SURVIVAL RATE;

EID: 0037093812     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10549     Document Type: Article

References (47)

1. Apoptosis by death factor
2. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
3. Monoclonal antibody-mediated tumor regression by induction of apoptosis
4. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice
5. Fas ligand mediates activation-induced cell death in human T lymphocytes
6. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas
7. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
8. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues
9. The role of FasL-induced apoptosis in immune privilege
10. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: Implications for immune-protection and cell turnover
11. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
12. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
13. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
14. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand
15. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
16. The grading of rectal cancer: Historical perspectives and a multivariate analysis of 447 cases
17. Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen
18. Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases
19. Human lung carcinomas express Fas ligand
20. Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor- infiltrating lymphocytes after in vitro as well as in vivo tumor expansion
21. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma
22. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas
23. FAP-1 in pancreatic cancer cells: Functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis
24. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
25. The Fas counterattack: Cancer as a site of immune privilege
26. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells
27. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy
28. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
29. The current contribution of molecular factors to risk estimation in neuroblastoma patients
30. CD95 antigen mutations in hematopoietic malignancies
31. Somatic mutations in the death domain of the Fas (Apo/CD95) gene in gastric cancer
32. Differential and mutually exclusive expression of CD95 and CD95 ligand in epithelia of normal pancreas and chronic pancreatitis
33. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation
34. CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice
35. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis
36. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation
37. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
38. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer
39. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2
40. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family
41. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
42. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
43. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street
44. The Fas counterattack in vivo: Apoptotic depletion of tumor- infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
45. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
46. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer